Pharmacyclics competitive analysis

Latest publications and patents of Pharmacyclics New

Explore the latest publications and patents granted to Pharmacyclics, showcasing their recent innovations and technological advancements.

Last updated on: Sep 28, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Pharmacyclics

Nov 22, 2023Pharmaceutical Formulations Of Bruton'S Tyrosine Kinase InhibtorGranted And Under Opposition
Oct 31, 2018Methods For The Treatment Of Her2 Amplified CancerRevoked
Jan 17, 2018Inhibitors Of Bruton'S Tyrosine KinaseRevoked

Explore Pharmacyclics's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 2, 2025
Patent NumberGrant DateTitleTotal Oppositions
Nov 22, 2023Pharmaceutical Formulations Of Bruton'S Tyrosine Kinase Inhibtor1
Oct 31, 2018Methods For The Treatment Of Her2 Amplified Cancer1
Jan 17, 2018Inhibitors Of Bruton'S Tyrosine Kinase1

Latest PTAB cases involving Pharmacyclics

Discover the latest PTAB cases involving Pharmacyclics, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 4, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Pharmacyclics

PGR2024-00009Nov 1, 2023BEIGENE USAPHARMACYCLICSFinal Written Decision
IPR2019-00865Mar 21, 2019SANDOZPHARMACYCLICSFinal Written Decision
IPR2015-01076Apr 20, 2015COALITION FOR AFFORDABLE DRUGS IVPHARMACYCLICSInstitution Denied

Peer Comparison New

IP litigation analysis comparing Pharmacyclics with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
PHARMACYCLICS - 3 - 3Non-Active
BEIGENE USA - - 1 - Highly Aggressive
COALITION FOR AFFORDABLE DRUGS IV - - 1 - Highly Aggressive
GENERICS UK212 - - - Highly Aggressive